DỮ LIỆU BÁO CÁO THƯỜNG NIÊN
CÁC CÔNG TY NIÊM YẾT NƯỚC NGOÀI

Báo cáo thường niên năm 2019 của Aerie Pharmaceuticals Inc

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its product candidates include Rhopressa, which is a once-daily eye drop that reduces intraocular pressure (IOP) in patients with glaucoma or ocular hypertension and is in Phase III registration trials; and Roclatan, a once-daily eye drop to reduce IOP that has completed Phase IIb clinical trial in patients with open-angle glaucoma and ocular hypertension.

TÊN CÔNG TY / COMPANY
Aerie Pharmaceuticals Inc

SÀN CHỨNG KHOÁN / STOCK EXCHANGE
NASDAQ (US)

MÃ CHỨNG KHOÁN / TICKER
AERI

KỲ BÁO CÁO
2019

NGÀNH / INDUSTRY
Drug Manufacturers - Major

LĨNH VỰC / SECTOR
Healthcare